BP issues stock acquisition rights as funding for the Phase I clinical trial of BP2202 in the United States. Potential issued shares: 34,500,000 shares; dilution: 24.84%; planned funds: 1,952 million yen. Exercise period: 2026\/10\/6\u20132027\/10\/6. Grants for exercise suspension, acquisition, and buyback, with a 3% discount. Use of funds: BP2202-related costs, other business operating funds, and new pipeline development costs. Cash and cash equivalents are about 1,580 million yen as of end of June 2026 to secure additional funds.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4594","jir_company_name":"BrightPath Biotherapeutics Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4594-20260918-02.pdf","jir_short_summary":"BP issues stock acquisition rights as funding for the Phase I clinical trial of BP2202 in the United States. Potential issued shares: 34,500,000 shares; dilution: 24.84%; planned funds: 1,952 million yen. Exercise period: 2026\/10\/6\u20132027\/10\/6. Grants for exercise suspension, acquisition, and buyback, with a 3% discount. Use of funds: BP2202-related costs, other business operating funds, and new pipeline development costs. Cash and cash equivalents are about 1,580 million yen as of end of June 2026 to secure additional funds.","jir_summary":"### Overview of Capital Policy\nThis supplementary document explains the purpose, terms, and use of funds for funding through the issuance of the 21st stock acquisition rights. Funds will be used for BP2202\u2019s US Phase I clinical trial costs, other operating funds, and new pipeline development costs. To limit dilution, exercise suspension, acquisition, and buyback provisions are included. The discount rate is set at 3% to balance appropriate risk adjustment and effectiveness.\n\n### Impact of Funding and Outlook\nAs of the end of June 2026, cash and cash equivalents stood at 1,580 million yen. Additional funding is deemed necessary to progress BP2202\u2019s clinical trials as planned, and staged financing will be carried out using stock acquisition rights. To mitigate dilution, provisions for exercise suspension, acquisition, and discount are set. Depending on funding adequacy and expenditure timing, future financing methods will be considered and disclosed.","jir_financial_highlights":"\u6f5c\u5728\u767a\u884c\u682a\u6570: 34,500,000 shares (Unknown)\n\u5e0c\u8584\u5316\u7387: 24.84% (Unknown)\n\u8abf\u9054\u4e88\u5b9a\u91d1\u984d: 1,952 \u767e\u4e07\u5186 (Unknown)\n\u521d\u884c\u4f7f\u4fa1\u984d: 57 yen (Unknown)\n\u4e0b\u9650\u884c\u4f7f\u4fa1\u984d: 29 yen (Unknown)\n\u767a\u884c\u6c7a\u8b70\u65e5: September 18, 2026 (Unknown)\n\u767a\u884c\u30fb\u5272\u5f53\u65e5: October 5, 2026 (Unknown)\n\u884c\u4f7f\u671f\u9593: October 6, 2026 \u2013 October 6, 2027 (Unknown)","jir_category":"","jir_hashtags":"#BrightPathBiotherapeutics, #CapitalPolicy, #StockAcquisitionRights, #BP2202, #ClinicalDevelopmentFunding","jir_key_figures":"\u6f5c\u5728\u767a\u884c\u682a\u6570: 34,500,000 shares\n\u5e0c\u8584\u5316\u7387: 24.84%\n\u8abf\u9054\u4e88\u5b9a\u91d1\u984d: 1,952 \u767e\u4e07\u5186","jir_meta_title":"BrightPath Biotherapeutics: Supplementary Explanation on Funds Through Stock Acquisition Rights Issue | Sep 2026","jir_meta_description":"BrightPath Biotherapeutics announces funding through the 21st issue of stock acquisition rights. Potential issued shares: 34,500,000; dilution: 24.84%; planned funds: 1,952 million yen. To be used for BP2202 clinical development costs, etc. Details on issuance terms, provisions, and usage.","jir_og_title":"BrightPath Biotherapeutics Announces Fundraising via Stock Acquisition Rights","jir_og_description":"BP conducts funding via stock acquisition rights toward initiating BP2202 clinical trials. Details on dilution, funding amount, and exercise terms disclosed.","jir_og_image_url":"\/assets\/og\/company-capital_policy.jpg","jir_chart_data_collection":"[]","ir_related_company":59787,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-115415","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n